Fig. 4: The effect of MK-8776/olaparib combination on IMR-32 cells does not depend on p.Val2716Ala ATM mutation.
From: A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
A Electropherograms representing DNA sequences obtained from control (ATMmut-CTR) and CRISPR/Cas9 reverted (ATMWT-Rev) IMR-32 clones. Black boxes indicate the mutated/reverted codon; arrowheads indicate blocking mutations in the reverted clones. B Cell death monitored by the trypan-blue exclusion assay on ATMmut-CTR and ATMWT-Rev clones treated with vehicle or MK-8776/olaparib (MK/Ola) combination, for 48 h. Data are reported as mean (+SD) of three independent experiments. C WB analysis of whole cell lysates obtained from the indicated cells after 9 and 24 h of treatment. Blots were probed with the indicated antibodies and β-actin was used as loading control. Data are representative of at least three replicates. The asterisk indicates the 89 kDa PARP1 cleaved fragment.
